Drug Profile
Japanese encephalitis vaccine - Sanofi
Alternative Names: ChimeriVax-JE; Imojev; JE-CV; Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®); Single-dose Japanese encephalitis vaccine - SanofiLatest Information Update: 06 Apr 2022
Price :
$50
*
At a glance
- Originator Acambis
- Developer Sanofi; Sanofi Pasteur
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Japanese encephalitis
Most Recent Events
- 15 Apr 2021 Discontinued - Phase-III for Japanese encephalitis (In adolescents, In children, In infants, Prevention, In adults) in Vietnam (SC)
- 15 Apr 2021 Discontinued - Phase-III for Japanese encephalitis (In infants, Prevention) in Taiwan (SC)
- 15 Apr 2021 Discontinued - Phase-III for Japanese encephalitis (Prevention) in India, USA (SC)